title: Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse.
abstract: Karyotype is an important prognostic factor in patients with newly diagnosed acute myeloblastic leukaemia (AML). The prognostic value of cytogenetics on the outcome of patients with AML in relapse has not yet been well defined. We analysed the clinical outcome of 152 patients with de novo, chemotherapy-treated AML in first relapse according to the cytogenetic classification of the United Kingdom Medical Research Council. The rate of second complete remission (CR) (88, 64 and 36%) and the probability of survival at 3 years (43, 18 and 0%) were significantly different between the favourable, intermediate and adverse cytogenetic risk groups, respectively. Compared to the favourable group, the relative risk (RR) of death (multivariate analyses) was 2.6 (confidence interval (CI): 1.5-4.4, P<0.001) for the intermediate and 3.7 (CI: 1.7-7.9, P=0.001) for the adverse group. The prognostic value of the duration of first CR was confirmed (RR of death: 2.0 (CI: 1.0-4.0) for each additional year in first CR), whereas the FLT3 mutation obtained at diagnosis did not markedly influence the outcome of patients with AML in relapse. In conclusion, our results indicate that both karyotype and the duration of first CR are independent prognostic factors for patients with de novo AML in first relapse.
authors.affiliation: Department of Internal Medicine I, Division of Haematology and Haemostasis, Vienna University Hospital, Vienna, Austria. Ansgar.Weltermann@akh-wien.ac.at
authors.forename: A
authors.initials: A
authors.lastname: Weltermann
authors.forename: C
authors.initials: C
authors.lastname: Fonatsch
authors.forename: O A
authors.initials: OA
authors.lastname: Haas
authors.forename: H T
authors.initials: HT
authors.lastname: Greinix
authors.forename: P
authors.initials: P
authors.lastname: Kahls
authors.forename: G
authors.initials: G
authors.lastname: Mitterbauer
authors.forename: U
authors.initials: U
authors.lastname: Jäger
authors.forename: B
authors.initials: B
authors.lastname: Kainz
authors.forename: K
authors.initials: K
authors.lastname: Geissler
authors.forename: P
authors.initials: P
authors.lastname: Valent
authors.forename: W R
authors.initials: WR
authors.lastname: Sperr
authors.forename: P
authors.initials: P
authors.lastname: Knöbl
authors.forename: I
authors.initials: I
authors.lastname: Schwarzinger
authors.forename: A
authors.initials: A
authors.lastname: Gleiss
authors.forename: K
authors.initials: K
authors.lastname: Lechner
mesh_terms: D000208:Acute Disease; D002965:Classification; D020732:Cytogenetic Analysis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007621:Karyotyping; D007951:Leukemia, Myeloid / Q000175:diagnosis* / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics; D012008:Recurrence; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome; D051941:fms-Like Tyrosine Kinase 3
chemical_list: D011518:Proto-Oncogene Proteins; C497970:FLT3 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3